Changes in amino-terminal portion of human B2 receptor selectively increase efficacy of synthetic ligand HOE 140 but not of cognate ligand bradykinin

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 284, Issue 6 53-6, 2003, Pages

  Schroeder, Christian ^a   Breit, Andreas ^b,e   Böning, Hilke ^c,e   Dedio, Jürgen ^b,d   Gera, Lajos ^f   Stewart, John ^f   Müller Esterl, Werner ^b  

^a Inst Cardiovasc/Arteriosclero R   (Germany)

^b GOETHE UNIVERSITY MEDICAL SCHOOL   (Germany)

^c UNIVERSITY OF MÜNSTER   (Germany)

^d SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

^e UNIVERSITÉ DE MONTRÉAL   (Canada)

^f UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Affinity; Kinin receptor; Receptor state

Indexed keywords

BRADYKININ; BRADYKININ B2 RECEPTOR; CHIMERIC KININ RECEPTOR 1; CHIMERIC KININ RECEPTOR 2; ICATIBANT; RECEPTOR; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; BINDING SITE; CELL STRAIN COS7; CHO CELL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; STRUCTURE ANALYSIS;

EID: 0038362735     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.00033.2003     Document Type: Article

References (37)

1. Arunlakshana O and Schild HO. Some quantitative uses of drug antagonists. Br J Pharmacol 14: 48-58, 1959.
2. Berridge MJ, Dawson RM, Downes CP, Heslop JP, and Irvine RF. Changes in the levels of inositol phosphates after agonist-dependent hydrolysis of membrane phosphoinositides. Biochem J 212: 473-482, 1983.
3. 2 receptor in vivo phosphorylation sites and their role in receptor function J. Biol Chem 276: 40431-40440, 2001.
4. Bhoola KD, Figueroa CD, and Worthy K. Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol Rev 44: 1-80, 1992.
5. Cheronis JC, Whalley ET, Nguyen KT, Eubanks SR, Allen LG, Duggan MJ, Loy SD, Bonham KA, and Blodgett JK. A new class of bradykinin antagonists: synthesis and in vitro activity of bissuccinimidoalkane peptide dimers. J Med Chem 35: 1563-1572, 1992.
6. Chidiac P, Hebert T, Dennis M, and Bouvier M. Inverse agonist activity of beta-adrenergic antagonists. Mol Pharmacol 45: 490-499, 1994.
7. Chidiac P, Nouet S, and Bouvier M. Agonist-induced modulation of inverse agonist efficacy at the beta 2-adrenergic receptor. Mol Pharmacol 45: 662-669, 1996.
8. 2 receptor antagonist, Hoe 140 (Icatibant), may act as mitogenic agonist. Br J Pharmacol 131: 1553-1560, 2000.
9. 2 receptor. Eur J Pharmacol 346: 291-298, 1998.
10. 2 bradykinin receptor activity determines the action of partial agonists as agonists or inverse agonists. Effect of basal desensitization. J Biol Chem 274: 29603-29606, 1999.
11. 2 receptor antagonist, Hoe 140, in isolated blood vessels from different species. Br J Pharmacol 112: 683-689, 1994.
12. Galzi JL, Edelstein SJ, and Changeux J. The multiple phenotypes of allosteric receptor mutants. Proc Natl Acad Sci USA 93: 1853-1858, 1996.
13. Gibbs CS, Coutre SE, Tsiang M, Li WX, Jain AK, Dunn KE, Law VS, Mao CT, Matsumura SY, Mejza SJ, Paborsky LR, and Leung LLK. Conversion of thrombin into an anticoagulant by protein engineering. Nature 378: 413-416, 1995.
14. Hock FJ, Wirth K, Albus U, Linz W, Gerhards HJ, Wiemer G, Henke S, Breipohl G, König W, Knolle J, and Schölkens BA. Hoe 140 a new potent and long acting bradykinin-antagonist: in vitro studies. Br J Pharmacol 102: 769-773, 1991.
15. Horstmeyer A, Cramer H, Sauer T, Müller-Esterl W, and Schroeder C. Palmitoylation of endothelin receptor A. Differential modulation of signal transduction activity by post-translational modification. J Biol Chem 271: 20811-20819, 1996.
16. 2 bradykinin receptor reveal a different pattern of contacts for peptidic agonists and peptidic antagonists. J Biol Chem 271: 28277-28286, 1996.
17. 2 subtypes. Br J Pharmacol 121: 526-530, 1997.
18. Kenakin T. The classification of seven transmembrane receptors in recombinant expression systems. Pharmacol Rev 48: 413-463, 1996.
19. Kenakin T. Efficacy in drug receptor theory: outdated concept or under-valued tool? Trends Pharmacol Sci 20: 400-405, 1999.
20. Labrecque J, Fargin A, Bouvier M, Chidiac P, and Dennis M. Serotonergic antagonists differentially inhibit spontaneous activity and decrease ligand binding capacity of the rat 5-hydroxytryptamine type 2C receptor in Sf9 cells. Mol Pharmacol 48: 150-159, 1995.
21. 2 receptor and bradykinin in HEK293 cells. Biochem J 355: 741-750, 2001.
22. 3H]bradykinin dissociates slowly. J Biol Chem 265: 9621-9627, 1990.
23. 2 receptor act as inverse agonists in rat myometrial cells. J Biol Chem 269: 25970-25973, 1994.
24. Leff P, Scaramellini C, Law C, and McKechnie K. A threestate receptor model of agonist action. Trends Pharmacol Sci 18: 355-362, 1997.
25. Lefkowitz RJ, Cotecchia S, Samama P, and Costa T. Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins. Trends Pharmacol Sci 14: 303-307, 1993.
26. Lin HY, Kaji EH, Winkel GK, Ives HE, and Lodish HF. Cloning and functional expression of a vascular smooth muscle endothelin 1 receptor. Proc Natl Acad Sci USA 88: 3185-3189, 1991.
27. Maggi CA and Schwartz TW. The dual nature of the tachykinin NK1 receptor. Trends Pharmacol Sci 18: 351-355, 1997.
28. 2 receptor induced by mutations in transmembrane helices III and VI. Mol Pharmacol 55: 92-101, 1999.
29. 2 bradykinin receptor. Proc Natl Acad Sci USA 88: 7724-7728, 1991.
30. 1 bradykinin receptor. J Biol Chem 269: 21583-21586, 1994.
31. Prestwich SA and Bolton TB. Inhibition of muscarinic receptor-induced inositol phospholipid hydrolysis by caffeine, beta-adrenoceptors and protein kinase C in intestinal smooth muscle. Br J Pharmacol 114: 119-126, 1995.
32. Regoli D and Barabé J. Pharmacology of bradykinin and related kinins. Pharmacol Rev 32: 1-46, 1980.
33. Samama P, Cotecchia S, Costa T, and Lefkowicz RJ. A mutation-induced activated state of the beta 2-adrenergric receptor. Extending the ternary complex model. J Biol Chem 268: 4625-4636, 1993.
34. Schroeder C, Beug H, and Müller-Esterl W. Cloning and functional characterization of the ornithokinin receptor Recognition of the major kinin receptor antagonist, HOE140 as a full agonist. J Biol Chem 272: 12475-12481, 1997.
35. Stewart JM, Gera L, Chan DC, Whalley ET, Hanson WL, and Zuzack JS. Potent, long-acting bradykinin antagonists for a wide range of applications. Immunopharmacology 36: 167-172, 1997.
36. Weiss JM, Morgan PH, Lutz MW, and Kenakin T. The cubic ternary complex receptor-occupancy model. III Resurrecting efficacy. J Theor Biol 181: 381-397, 1996.
37. Wirth K, Hock FJ, Albus U, Linz W, Alpermann HG, Anagnostopoulos H, Henk S, Breipohl G, König W, Knolle J, and Schölkens BA. Hoe 140 a new potent and long acting bradykinin-antagonist: in vivo studies. Br J Pharmacol 102: 774-777, 1991.